MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10.286 57.05
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-19M 173M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. märts 2026, 23:14 UTC

Market Talk

Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. märts 2026, 21:24 UTC

Market Talk

Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.